News

Please find below all relevant news regarding our Group.
Click on a headline in order to read the full article.

Goodbye Sara Gutiérrez

08/17/2022
Sara Gutiérrez Hernández has left the group and she joined the Lilly pharma company. Good luck Sara!

Sara Gutiérrez Hernández has just left the group and she has joined the pharmaceutical Eli Lilly and Company, in Madrid (Spain), for a R&D-chemistry position.

Best of luck Sara!

Goodbye Xandro Vidal and Joan Miguel

08/01/2022
Xandro Vidal Pereira and Joan Miguel Ávila have left the group to pursue their postdoctoral careers. Good luck to you both!

Xandro Vidal Pereira and Joan Miguel Ávila, two students that started at the group as CiQUS summer fellows and then went for their MSc and PhD also with us, have just left MetBioCat and they will pursue their postdoctoral careers.

Best of luck Xandro and Joan!

Goodbye Soraya Learte

07/30/2022
Soraya Learte-Aymamí has left the group and she joined the Janssen pharma company. Good luck Soraya!

Soraya Learte-Aymamí has just left the group and she has joined the Janssen pharma company, in Spain, for a MSL position.

Best of luck Soraya!


Two in a row!! A second publication in collaboration with Prof. E. Vázquez is also on-line

06/23/2022
Extremely happy to announce the second 2022 collaborative paper is already published

We are really glad to share this second 2022 collaborative paper, published at Commun. Chem., has been already accepted and it's available through the journal website. The communication is entitled "Controlling oncogenic KRAS signaling pathways with a Palladium-responsive peptide" and authored by S. Learte-Aymamí, P. Martin-Malpartida, L. Roldán-Martín, G. Sciortino, J. R. Couceiro, J.-D. Maréchal, M. J. Macias, J. L. Mascareñas and M. E. Vázquez.

Abstract: RAS oncoproteins are molecular switches associated with critical signaling pathways that regulate cell proliferation and differentiation. Mutations in the RAS family, mainly in the KRAS isoform, are responsible for some of the deadliest cancers, which has made this protein a major target in biomedical research. Here we demonstrate that a designed bis-histidine peptide derived from the αH helix of the cofactor SOS1 binds to KRAS with high affinity upon coordination to Pd(II). NMR spectroscopy and MD studies demonstrate that Pd(II) has a nucleating effect that facilitates the access to the bioactive α-helical conformation. The binding can be suppressed by an external metal chelator and recovered again by the addition of more Pd(II), making this system the first switchable KRAS binder, and demonstrates that folding-upon-binding mechanisms can operate in metal-nucleated peptides. In vitro experiments show that the metallopeptide can efficiently internalize into living cells and inhibit the MAPK kinase cascade.






External link: https://www.nature.com/articles/s42004-022-00691-7

Our most recent collaboration is already on-line at Chem. Commun.

06/22/2022
So glad to announce our first 2022 collaborative paper is already published

We are very happy to share our Chem. Commun. paper in collaboration with Vázquez & Vázquez research group, among others, has been accepted and it's already available through the journal website. This work is entitled "Selective recognition of A/T-rich DNA 3-way junctions with a three-fold symmetric tripeptide" and authored by J. Gomez-Gonzalez, L. Martinez-Castro, J. Tolosa-Barrilero, A. Alcalde-Ordoñez, S. Learte-Aymamí, J. L. Mascareñas, J. C. García-Martínez, J. Martínez-Costas, J.-D. Maréchal, M. Vázquez and E. Vázquez.

Abstract: Non-canonical DNA structures, particularly 3-Way Junctions (3WJs) that are transiently formed during DNA replication, have recently emerged as promising chemotherapeutic targets. Here, we describe a new approach to target 3WJs that relies on the cooperative and sequence-selective recognition of A/T-rich duplex DNA branches by three AT-Hook peptides attached to a three-fold symmetric and fluorogenic 1,3,5-tristyrylbenzene core.





External link: https://pubs.rsc.org/en/content/articlelanding/2022/CC/D2CC02874C

Congratulations to Soraya Learte, who received the Honorable Mention for the 2022 IUPAC-Solvay International Award for Young Chemists

05/18/2022
Our group member has received her awarded PhD in April 2021

We are celebrating today the great success of Dr. Soraya Learte, who has been awarded with one of the threee honorable metions of the 2022 IUPAC-Solvay International Award for Young Chemists. The award is a consequence of her commitment and also her stunning results during her doctoral studies at our research group. Her PhD thesis is entitled "Metallopeptides and Metalloproteins in Chemical Biology: from DNA Binding to Intracellular Catalysis".

During her PhD studies, Soraya has mainly worked in the design, synthesis, and application of metallopeptides and metalloproteins within the area of Chemical Biology.






External link: https://iupac.org/winners-of-the-2022-iupac-solvay-international-award-for-young-chemists/